Impact Report 2023
23
IMPACT REPORT 2023
1
Contents
2
Executive summary
4
Mission
6
Our global impact in 2023
8
Bringing hope to more people, closer to home
10
Partnerships, innovations and new geographies
14
Looking ahead
16
Acknowledgements
18
Glossary
19
IMPACT REPORT 2023
IMPACT REPORT 2023
3
Executive Summary
4
IMPACT REPORT 2023
This World Cancer Day 2024, I’m proud to share Icon Group’s Impact Report outlining our contribution and commitment to tackling the growing cancer burden through innovation, research, and comprehensive cancer care for people around the world. This report shares our teams’ efforts through 2023 as leading providers across our divisions – cancer care, research, pharmacy, and compounding – combining to deliver care through 3.5 million patient interactions around the world including Australia, New Zealand, Singapore, Mainland China, Hong Kong and beyond. Our global team of over 3,500 dedicated healthcare professionals delivered more than 500 thousand treatments across radiation oncology and day oncology, recruited over 270 patients to clinical trials, and compounded more than 1.2 million infusions. Alongside this, we introduced new technologies and treatment techniques, moving Icon a step forward in the fight against cancer and our ability to help and provide hope to more people, families, and communities. With our solid foundation of strong industry partnerships, an experienced global network of specialists and expert teams committed to continually improving healthcare, Icon expanded our operations to bring our services to new regions. Our partnership with Nuffield Health will see us deliver treatment in the United Kingdom, and our joint venture with Sunsuria Healthcare establishes Icon in Malaysia to help enhance cancer care in the ASEAN region. I’d like to share Icon’s thanks to our patients, people and our partners – together, we’re providing world-class care that feels like home and building hope for a brighter future. Many thanks
Mark Middleton OAM Icon Group CEO
IMPACT REPORT 2023
5
UNITED KINGDOM
Nuffield Health partnership
Five cancer centres and one management service agreement
Sunsuria Healthcare partnership
MAINLAND CH
Management service agreement
M
Seven cancer centres including flagship Mt Alvernia integrated centre Three centres delivering research One health screening centre
Mission Our mission is to deliver the best care possible, to as many people as possible, as close to home as possible. 6
IMPACT REPORT 2023
3.5m
patient interactions across medical oncology, haematology, radiation oncology, pharmacy, compounding, surgical oncology and research delivered by more than 3,500 employees
Two cancer centres
HINA
Two specialist centres
HONG KONG
VIETNAM
Management of 70+ pharmacies Over 38 cancer centres
MALAYSIA SINGAPORE
23 centres delivering research Drug stability and research lab Four TGA licensed compounding facilities
AUSTRALIA
NEW ZEALAND
One cancer centre Research capabilities One GMP licensed compounding facility
Note: Data 01/01/2023 – 31/12/2023
IMPACT REPORT 2023
7
Our Global Impact in 2023 SIGNED A JOINT VENTURE
Partnership with Nuffield Health to deliver cancer care in the UK
6
new linear accelerators installed
partnership with Sunsuria Health to provide cancer care in Malaysia
10
FIRST
25% increase in stereo sessions and
350+ global doctor network
motion management systems installed across Australia, including Varian’s IDENTIFY SGRT system
Introduced stereotactic radiation therapy to four more sites – 38 centres now have stereo capability
= 97% stereo coverage
Launched Icon’s Theranostics program marking the start of precision medicine Achieved above National Standard in Quality accreditation 8
IMPACT REPORT 2023
60+ publications by Icon’s network of doctors and healthcare professionals
in Southern Hemisphere to introduce Varian’s HyperSight technology delivering cutting-edge, precision imaging
=
15%
increase in doctor network in Australia alone Delivered a patient navigation program in Kigali, Rwanda
3
new cancer centres offering clinical trials
275
12%
patients recruited to clinical trials across 24 locations in Australia, New Zealand and Singapore
INCREASED MEDICATION SHELF-LIFE BY SEVERAL DAYS Providing greater access to specialised care for patients undergoing breast, skin, and gastrointestinal cancers, and multiple sclerosis
patients
1.2+ million infusions delivered
881
current clinical trial patients in 193 active clinical trials
Dispensed medication to
1m+
increase in Principal Investigators
Opened a state-of-theart TGA licensed compounding facility in Woodville, South Australia
Secured contract to manage pharmacy services to
FOUR UnitingCare Queensland hospitals
236
active clinical trials at Slade Health, and help support 380+ clinical trials
IMPACT REPORT 2023
9
Bringing hope to more people, closer to home In another year of delivering exceptional care, we’re proud to share how our dedicated teams and technology and research capabilities are helping provide new hope and more time for patients, families, and communities across the globe…
There is absolutely no doubt that in my mind as a result of the treatment and trial I have been so fortunate to have received that my life has been extended far beyond what I could have expected.” Ian, Icon clinical trial patient I didn’t realise that there were people out there somewhere making my medication especially for me, I just assumed the pharmacist took it off the shelf just like this. Thank all of your people for doing that.” Patient on their first day of treatment We didn’t want to just sit in one location and settle for patient first, explorer second. With centres around Australia, Icon means we can keep travelling and lead the life that we want to live to get out and see all the beautiful things around us and simply live life.” Bronwyn, Icon Australia patient I’m grateful to be able to participate in a clinical trial and by doing so, I can play a part in the development and improvement of medications to help fight cancer.” Ong Guat Eng, Icon Singapore patient I wore a different pair of colourful socks to treatment every day. The Icon team surprised me on my last day of treatment by wearing their own colourful socks. They all had their trouser bottoms turned up to expose the socks and I thought this was a wonderful gesture, I was almost overcome with emotion.” Michael, Icon Australia patient
10
IMPACT REPORT 2023
The latest radiation therapy technology changing lives every day Rockingham resident, Robert is grateful to have world-class cancer care close to home. Robert is one of the first patients to be treated on Icon Cancer Centre Rockingham’s second linear accelerator (linac), which went live in June 2023. The centre, in Western Australia, is home to a new advanced Varian TrueBeam linac with cutting-edge IDENTIFY technology, which offers patients the option to have tattoo-less treatment. This technology enhances treatment accuracy, reduces treatment duration and eliminates the need for permanent markings, which some patients find to be an unwelcome daily reminder of their cancer. The linac is also equipped with Varian’s HyperArc technology for patients with multiple brain lesions or metastasis to the brain. As the first provider in Western Australia, this advanced technique delivers precise radiation therapy to multiple intracranial lesions with greater efficiency, speed, accuracy, and patient comfort while limiting doses to surrounding healthy brain tissue. Robert (79) was diagnosed with prostate cancer in November 2022. Faced with the prospect of a two-hour round trip each day to have radiation therapy treatment at Fiona Stanley Hospital,
where he had his diagnostic tests, Robert was thrilled to discover he could have his treatment just 10 minutes from home at Icon Cancer Centre Rockingham. “It was magic being able to have my treatment close to home,” says Robert, who finished 39 sessions of radiation therapy treatment in July 2023. “The centre is 10 minutes from home, so I could drive myself to treatment and it didn’t take up much of my day. “The team at Rockingham are wonderful. It’s like a family atmosphere there. The staff are friendly, and you get to know other patients while you are waiting for treatment. “I had treatment on the new machine towards the end of my treatment cycle. I think it’s great that more local patients can be treated at Icon with the best technology available.” Robert celebrated his 80th birthday in November with a getaway to Busselton with his wife, Joyce. In 2021, Icon became the first in the southern hemisphere to install IDENTIFY technology, and now has 17 around the country.
It was magic being able to have my treatment close to home.” Robert, Icon patient
IMPACT REPORT 2023
11
Turning the dial in regional Victoria In April 2023, Icon, in partnership with Mildura Health Private Hospital, opened a state-of-the-art cancer centre in the heart of Mildura in regional Victoria, Australia. This centre brought world-class comprehensive cancer care to the local community who previously had to travel to Bendigo, Melbourne or Adelaide to receive treatment, often at a considerable cost. In under a year, the centre has transformed local care, completing more than 3,200 individual radiation therapy treatment sessions with over 130 patients completing their radiation therapy treatment. The team has brought care closer to home and have saved an estimated total of 800,000 kilometres of travel, eliminating some of the many burdens associated with a cancer diagnosis. Denise is one of the many residents benefitting from the local centre. As a registered nurse with a distinguished career in healthcare, Denise has spent over 30 years caring for others. As the General Manager for the Lower Western Sector of the Far West Local Health District, Denise oversees health services across Broken Hill, Menindee, Wentworth, Dareton, Balranald, Ivanhoe, White Cliffs, Tibooburra and Wilcannia.
12
IMPACT REPORT 2023
“It has made us have very real and confronting conversations as a family. But I don’t want my cancer to define me. While my cancer can’t be cured, I plan to live with it for as long as I can.” To help with the pain management of her cancer, Denise was referred to the recently opened Icon Cancer Centre Mildura for radiation therapy treatment. Palliative radiation therapy can help improve quality of life by controlling symptoms associated with cancer and reducing pain levels. These services support a population of over 36,000 people across the second largest geographic area (194,949m2) of all the local health districts in NSW. With long days and extensive travel required for her job, Denise wasn’t overly concerned when she started feeling run-down in early 2023.
Denise says she is “extremely grateful” for being able to access this treatment locally.
“I was feeling tired, but I put it down to my busy lifestyle. I then noticed a lump in my breast and my nipple started changing in appearance. At the time I didn’t have a regular GP, so I went to the local hospital,” said Denise.
If Icon Mildura wasn’t here, I would have had to travel to Melbourne to have the radiation therapy. That’s four weeks away from my loved ones.”
The mother-of-two was sent for a series of scans, which revealed a heartbreaking diagnosis – metastatic breast cancer. “I was told there was nothing they could do, as it was in my bones. I was shattered. It was so confronting. I had aches and pains, and I was tired, but I didn’t think anything was seriously wrong.” Denise said her family, especially her husband Tim, who is also a registered nurse and health service manager, and the couple’s two daughters Grace and Lily-Rose have rallied around her since the diagnosis. And it is this support that is keeping Denise as positive as she can be.
Thanks to Icon, I could stay in Mildura. Every day I could take my daughter to school and pick her up. That time I get to spend with her is precious. Tim was also able to come to my appointments and keep working. It gave us more control over our lives during this difficult time. I don’t think I would be as well centred as I am if I had to travel for treatment.” Learn more about Icon Cancer Centre Mildura.
IMPACT REPORT 2023
13
Regional forums
Partnerships, innovations and new geographies Cancer touches everyone in some way. Over the next two decades, the data shows that the number of new cases is expected to rise by approximately 70%.1 Icon Group is built on the belief that together we can do more. With a proven track record of strong partnerships, the year saw Icon continue to nurture existing partnerships and build new ones to deliver more care to more people. From local to national and global partnerships, 2023 was a transformative year for the Icon team. We announced milestone partnerships in new geographies and opened several new cancer centres and a state-of-the-art TGA licensed compounding facility which have increased our capacity to deliver care to where it’s needed. Here are some of our 2023 highlights. 1
14
World Health Organisation
IMPACT REPORT 2023
The year saw the next phase in Icon’s commitment to partnering with patient advocacy groups to improve the patient experience, starting from the ground up. Two regional forums were held in Townsville, Queensland and Maitland, New South Wales. These forums brought together leading patient advocacy and support groups to highlight gaps in cancer patient experience and trigger ongoing conversations to find solutions that respond to challenges faced by people living with cancer in Australia. Icon will continue to host more regional forums in 2024 and deliver practical solutions to improve cancer care. Learn more here.
Entering the United Kingdom August 2023 marked Icon’s entry into the United Kingdom signing a strategic partnership with Nuffield Health, the UK’s largest healthcare charity. Together Nuffield and Icon have ambitions to deliver the highest-quality oncology care and a seamless experience to patients in the UK. Learn more here.
Elevating care in Southeast Asia In September 2023, Icon Group announced a new joint venture partnership with Sunsuria Healthcare to help narrow the gap in access to care in Malaysia. The first centre in this partnership opened in January 2024 at Island Hospital, Penang. Learn more here.
Best-in-class pharmacy services In October 2023 Slade Pharmacy, supported by Icon Group was awarded the contract for the management of pharmacy services to four UnitingCare Queensland (UCQ) hospitals. This recognises Slade’s commitment to patient care, innovation, and best practice digital and clinical pharmacy services. Learn more here.
Quality compounding November 2023 saw the official opening of Slade Health’s fifth compounding facility and the first in South Australia. This TGA licensed facility has the capacity to deliver more than 300,000 chemotherapy infusions annually. Learn more here.
An Integrated Global Network Leveraged our global network and delivered innovations to improve access to care. This included radiation therapy (RT) plan pooling which assesses variance in RT workloads and utilises Icon’s global network of RTs to plan treatments more efficiently anywhere in the world.
IMPACT REPORT 2023
15
Looking ahead We believe that every patient deserves the best care possible, where and when they need it most. Icon has an established a proven and effective integrated model of care, partnering with local expertise and applying regional insights to develop tailored services to meet current and future patient and clinician needs anywhere in the world. We have an ambitious five-year strategy to help us continue to deliver world-leading, integrated healthcare and address the growing global cancer burden. Over the next five years we aim to grow our global network from 3.5 million patient interactions to 6 million and bring the latest in treatments to more communities. In 2024 and beyond, Icon looks forward to investing in people who make a difference and ensuring our values-led organisation grows and diversifies to meet the demand for cancer treatment and provide the best possible patient care.
16
IMPACT REPORT 2023
New Geographies
Future Healthcare
Excellence in Care
We’re growing and diversifying our services and care to existing and new regions, investing in our people, doctors, and technology to deliver exceptional healthcare.
We will continue to invest in new cancer treatments, technology, and research to be at the forefront of healthcare.
We will strive to deliver our care and services sustainably investing in new systems to improve patient experience and streamline operations for success.
2024 and beyond will see Icon build on our Australia footprint with a focus on regional communities, and mature our presence in the UK.
We will broaden our clinical trials network globally and expand our theranostics capabilities and digital pharmacy solutions to deliver the best possible patient and customer experience.
We will also focus on our ESG journey. Across environment, social and governance we’ve set goals to leave a positive legacy for patients, people and planet. IMPACT REPORT 2023
17
Acknowledgements Icon would like to warmly thank all the doctors, team members, patients, customers and partners for their dedication and contribution to the future of healthcare. We would also like to acknowledge the work of Icon Cancer Foundation (ICF), an independent not-for-profit registered charity whose mission is to promote, initiate and support clinical trials and research, striving towards a brighter future for cancer patients and communities. ICF is committed to improving patient access to new and emerging treatments by raising awareness of and sponsoring Investigator Initiated Trials (IITs). This research advances treatments for everyone and offers hope to those living with cancer now and in the future. Learn more about Icon Cancer Foundation at iconcancerfoundation.org.au
18
IMPACT REPORT 2023
Glossary GMP Good Manufacturing Practices (GMP) is the aspect of quality assurance that ensures that medicinal products are consistently produced and controlled to the quality standards appropriate to their intended use.
HyperArc HyperArc is one of the latest technological advancements from Varian Medical Systems. It provides an end-to-end solution for multiple brain tumours and is primarily used to treat secondary brain tumours (those that have spread from other parts of the body) and precisely targets multiple tumours while reducing side effects.
IDENTIFY Is Varian Medical System’s Surface Guided Radiation Therapy (SGRT) technology, also known as tattoo-free radiation therapy which uses advanced camera technology to facilitate 3D, real time tracking of the skin’s surface during set-up and patient treatment, eliminating the need for permanent tattoos used in traditional radiation therapy.
Linac A linear accelerator, also referred to as a Linac is a machine that deliver radiation to cancer tumours with pinpoint accuracy.
Patient interaction In this report a patient interaction is defined by episodes of care. This includes, but is not limited to, radiation therapy treatment sessions, production of compounded medications and day oncology infusions.
Stereotactic radiation therapy Stereotactic radiation therapy (SRT), also called stereotactic body radiation therapy (SBRT) or stereotactic ablative radiation therapy (SABR) is a type of external radiation therapy treatment. It is an advanced technique used to treat small, well-defined tumours or high-risk postoperative areas. It can be used to treat both primary and metastatic (sometimes referred to as secondary tumours).
TGA Therapeutic Goods Administration (TGA) is Australia’s government authority responsible for evaluating, assessing and monitoring products that are defined as therapeutic goods.
Theranostics Theranostics is a personalised form of cancer treatment that combines diagnostic imaging to identify a person’s cancer cells and targeted therapy to treat their cancer. It aims to slow the growth and spread of cancer, relieve symptoms and maintain or improve quality of life. IMPACT REPORT 2023
19
ICON GROUP HEAD OFFICE Level 1, 22 Cordelia Street Australia T +61 7 3737 4500 E media@icon.team icongroup.global 20
IMPACT REPORT 2023
Follow Icon Group on LinkedIn
GLB GRP 113092_2401
South Brisbane QLD 4101